Objective-G protein-coupled receptor kinase-5 (GRK5) is a widely expressed Ser/Thr kinase that regulates several atherogenic receptors and may activate or inhibit nuclear factor-B (NF-B). This study sought to determine whether and by what mechanisms GRK5 affects atherosclerosis. Methods and Results-Grk5 Ϫ/Ϫ /Apoe Ϫ/Ϫ mice developed 50% greater aortic atherosclerosis than Apoe Ϫ/Ϫ mice and demonstrated greater proliferation of macrophages and smooth muscle cells (SMCs) in atherosclerotic lesions. In Apoe Ϫ/Ϫ mice, carotid interposition grafts from Grk5 Ϫ/Ϫ mice demonstrated greater upregulation of cell adhesion molecules than grafts from wild-type mice and, subsequently, more atherosclerosis. By comparing Grk5 Ϫ/Ϫ with wild-type cells, we found that GRK5 desensitized 2 key atherogenic receptor tyrosine kinases: the platelet-derived growth factor receptor-␤ in SMCs, by augmenting ubiquitination/degradation; and the colony-stimulating factor-1 receptor (CSF-1R) in macrophages, by reducing CSF-1-induced tyrosyl phosphorylation. GRK5 activity in monocytes also reduced migration promoted by the 7-transmembrane receptor for monocyte chemoattractant protein-1 CC chemokine receptor-2. Whereas GRK5 diminished NF-B-dependent gene expression in SMCs and endothelial cells, it had no effect on NF-B activity in macrophages. Conclusion-GRK5 attenuates atherosclerosis through multiple cell type-specific mechanisms, including reduction of SMC and endothelial cell NF-B activity and desensitization of receptor-specific signaling through the monocyte CC chemokine receptor-2, macrophage CSF-1R, and the SMC platelet-derived growth factor receptor-␤. (Arterioscler Thromb Vasc Biol. 2012;32:308-316.)
uitously expressed member of the GRK family of Ser/Thr kinases, originally characterized for their ability to phosphorylate agonist-activated 7-transmembrane receptors. 1 GRK5 can regulate signaling through numerous 7-transmembrane receptors, 1,2 several of which have been implicated in atherogenesis. [3] [4] [5] [6] [7] [8] In addition, GRK5 can phosphorylate several non-7transmembrane receptor proteins that have been implicateddirectly or indirectly-in atherogenesis. GRK5-mediated phosphorylation of p53 triggers its degradation in model cells, 9 and p53 deficiency aggravates atherosclerosis by reducing apoptosis of macrophages (Ms) in the arterial intima. 10 When overexpressed in cardiomyocytes, GRK5 can phosphorylate histone deacetylase-5, promote its export from the nucleus, and thereby deinhibit myocyte enhancer factor-2 11 -a transcription factor that upregulates proatherogenic genes. 12 By phosphorylating IB␣, GRK5 may increase proatherogenic nuclear factor-B (NF-B) signaling down-stream of Toll-like receptor 4 (TLR4) and tumor necrosis factor receptor-1 (TNFR1). 13, 14 Conversely, as suggested by overexpression studies in endothelial cells (ECs), 15 GRK5 may associate with IB␣ in the nucleus, thereby limit NF-B activity, and consequently exert antiatherogenic influences. 16 Lastly, GRK5 phosphorylates the platelet-derived growth factor receptor-␤ (PDGFR␤) and thereby alters signaling through this proatherogenic receptor tyrosine kinase in vascular smooth muscle cells (SMCs)-by reducing PDGFR␤-triggered inositol phosphate signaling, reducing PDGFR␤ catalytic activity, and enhancing PDGFR␤-dependent Src activation. 17, 18 Thus, GRK5 appears to have multiple cell type-and receptor-specific activities that are potentially anti-or proatherogenic.
To understand atherogenic effects of GRK5 activity integrated over multiple cell types, we studied atherosclerosis in apolipoprotein E-deficient (Apoe Ϫ/Ϫ ) mice that were ϩ/ϩ or Ϫ/Ϫ at the Grk5 locus. Furthermore, by using SMCs, ECs, Ms, and monocytes derived from wild-type (WT) and congenic Grk5 Ϫ/Ϫ mice, we investigated cell type-specific effects of GRK5 on proatherogenic signaling and cellular activities.
Methods
For complete Methods, please see supplemental materials, available online at http://atvb.ahajournals.org.
Mice
All mice were congenic on the C57BL/6 background. Our Grk5 Ϫ/Ϫ mice 17 were crossed with Apoe Ϫ/Ϫ mice (The Jackson Laboratory) to obtain sibling Apoe Ϫ/Ϫ /Grk5 Ϫ/Ϫ and Apoe Ϫ/Ϫ /Grk5 ϩ/ϩ mice used for generating congenic lines. Primary cell lines were obtained from Grk5 Ϫ/Ϫ and WT mice.
Atherosclerosis Experiments
Male Apoe Ϫ/Ϫ and Apoe Ϫ/Ϫ /Grk5 Ϫ/Ϫ mice were fed a Western diet for 12 weeks from age 5 weeks; aortic harvest and atherosclerosis quantitation were performed as described. 19, 20 To quantitate proliferating cells, we injected mice intraperitoneally 24 hours before euthanization with 5-ethynyl-2Ј-deoxyuridine. 21 Orthotopic interposition grafting of the common carotid artery was performed as described. 20, 22 Carotid endothelial denudation was performed as described. 19 Quantitation was performed by observers blinded to specimen identity.
Cell Culture and Assays
Mouse aortic SMCs and ECs were isolated by enzymatic digestion of aortas and passaged as described. 18, 19 Ms were derived from bone marrow precursors. 23 Monocytes were isolated by negative selection from bone marrow of WT and Grk5 Ϫ/Ϫ mice matched for age and gender, using the EasySep Monocyte Enrichment Kit (StemCell Technologies, Inc). Proliferation, migration, and immunoprecipitation studies were performed as described. 17 
Results

GRK5 Attenuates Atherosclerosis
To determine the effect of GRK5 activity on atherosclerosis, we first compared aortic atherosclerosis between congenic male Apoe Ϫ/Ϫ mice that were ϩ/ϩ or Ϫ/Ϫ at the Grk5 locus. These mice had equivalent systolic blood pressures and heart rates: 117Ϯ7 versus 116Ϯ8 mm Hg and 650Ϯ40 versus 640Ϯ40 beats per minute, respectively (nϭ10/genotype). After consuming a Western diet for 12 weeks, these mice also had equivalent weights (30Ϯ3 and 31Ϯ4 g) and serum levels of total cholesterol, high-density lipoprotein cholesterol, and triglycerides: 36Ϯ3 versus 39Ϯ2, 1.2Ϯ0.2 versus 1.0Ϯ0.2, and 2.7Ϯ0.2 versus 2.7Ϯ0.1 mmol/L, respectively, for Grk5 ϩ/ϩ /Apoe Ϫ/Ϫ and Grk5 Ϫ/Ϫ /Apoe Ϫ/Ϫ mice (nՆ18/genotype). Nonetheless, cholesteryl ester-rich Sudanophilic lesions occupied 50% more of the aortic intimal surface area in Grk5 Ϫ/Ϫ /Apoe Ϫ/Ϫ than in Grk5 ϩ/ϩ /Apoe Ϫ/Ϫ mice (PϽ0.002, Figure 1A ). Thus, systemic expression of GRK5 reduced atherosclerosis through mechanisms that appear independent of hemodynamic and lipid parameters. Furthermore, the reduction of atherosclerosis in GRK5-expressing mice correlated with reduction of cell proliferation in the aortic media and atherosclerotic lesions, in both SMC-rich and M-rich regions of the plaques ( Figure 1B ).
We reasoned that GRK5 would likely mediate antiatherogenic activity in arterial wall cells, because GRK5 alters SMC signaling triggered by the atherogenic SMC PDGFR␤ 17, 24 and because overexpression of GRK5 in ECs can reduce serum-induced IB␣ degradation and NF-B activity. 15 To test this possibility, we performed orthotopic (interposition) grafting of carotid arteries from congenic WT and Grk5 Ϫ/Ϫ mice into congenic Apoe Ϫ/Ϫ mice. This model of accelerated atherosclerosis produces complex plaques comprising necrotic cores, cholesterol clefts, and SMC-rich fibrous caps and responds to genetic manipulation in a manner concordant with aortic atherosclerosis. 20 We first harvested these carotid grafts 2 weeks postoperatively, before Ms infiltrated the intima, to observe preatherosclerotic changes in SMC and EC protein expression. 20 In these 2-week carotid grafts, GRK5 protein expression increased 2.3Ϯ0.3-fold compared with cognate unoperated WT carotid arteries (Supplemental Figure  III) , consistent with the concept that GRK5 activity is antiatherogenic in SMCs and ECs. Moreover, several atherogenic parameters were augmented in Grk5 Ϫ/Ϫ as compared with WT preatherosclerotic grafts. PDGFR␤ activation was 2-fold greater in Grk5 Ϫ/Ϫ carotids, as assessed by immunofluorescence for the phospho-Tyr1021 PDGFR␤ ( Figure  2 )-even though total PDGFR␤ levels were equivalent to WT (Supplemental Figure III) . Greater NF-B activity manifested in Grk5 Ϫ/Ϫ than in WT carotids, as judged by increases in intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and monocyte chemoattractant protein-1 protein expression ( Figure 2 ). 22 This augmented atherogenic signaling and inflammatory gene expression in Grk5 Ϫ/Ϫ carotids evolved into more extensive atherosclerosis than obtained in WT carotid grafts: 6 weeks postoperatively, Grk5 Ϫ/Ϫ carotids had 2-fold larger atheromata than WT carotid grafts ( Figure 2 ). Thus, even when expressed just in arterial wall cells, GRK5 reduced atherogenesis.
GRK5 Reduces Nonatherosclerotic Neointimal Hyperplasia
Because GRK5 activity reduced arterial wall contributions to atherosclerosis, we expected that GRK5 would reduce SMC migration and proliferation evoked by inflammatory stimuli in a nonatherogenic setting, too. 19 To test this hypothesis, we denuded the endothelium of the common carotid artery in WT and Grk5 Ϫ/Ϫ mice. This procedure produces neointimal hyperplasia comprising only SMCs from the artery itself, as we have shown with green fluorescent protein-transgenic bone marrow transplantation. 19 Although carotid arteries of WT and Grk5 Ϫ/Ϫ mice were morphologically indistinguishable before intervention, neointimal area and luminal stenosis 4 weeks after endothelial denudation were 3.5and 8-fold greater, respectively, in Grk5 Ϫ/Ϫ than in WT mice (Supplemental Figure IV) . Congruently, Grk5 Ϫ/Ϫ arteries also demonstrated 1.8Ϯ0.2-fold greater PDGFR␤ activation (evinced by phosphorylation on Tyr1021) in medial SMCs 2 weeks after endothelial denudation, before substantial neointimal hyperplasia supervened (Supplemental Figure V ).
GRK5 Diminishes NF-B-Driven Gene Expression in ECs
Data from our carotid grafts suggest that physiologically expressed GRK5 diminishes the expression of NF-Bdependent 16 cell adhesion molecules in arterial wall cells ( Figure 2 ). To ascertain the effects of GRK5 on NF-B activation specifically in ECs, we stimulated Grk5 Ϫ/Ϫ and WT ECs with TNF 16 and assayed protein from the combined cytoplasmic plus nuclear EC compartments. 15 Over a 2-hour time course, IB␣ levels were 35Ϯ9% lower in Grk5 Ϫ/Ϫ than in WT ECs (PϽ0.02, Figure 3A ), whereas phospho-Ser32/ 36-IB␣ levels (normalized to total IB␣ levels) were equivalent in Grk5 Ϫ/Ϫ and WT ECs ( Figure 3A ). Congruently, after 24 hours, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression were 1.6-to 2.2-fold higher in Grk5 Ϫ/Ϫ than in WT ECs ( Figure 3B and 3C)even though TNFR1 and NF-B p65 levels were equivalent in Grk5 Ϫ/Ϫ and WT ECs ( Figure 3D ). Thus, these data support the idea that physiological GRK5 activity reduces cytokine-promoted NF-B activity in ECs, just as GRK5 overexpression does. 15 Figure 2 . Arterial wall-specific G protein-coupled receptor kinase-5 (GRK5) deficiency increases platelet-derived growth factor receptor-␤ (PDGFR␤) activation, nuclear factor-B (NF-B)-dependent gene expression, and atherosclerosis. Carotid arteries from congenic wild-type (WT) or Grk5 Ϫ/Ϫ mice were placed as orthotopic interposition grafts into congenic Apoe Ϫ/Ϫ mice. A, Grafts were harvested 2 weeks postoperatively, before intimal macrophages (Ms) could be identified. Serial frozen sections were stained with hematoxylin/eosin (H&E) or fluorescently immunostained for the indicated proteins and Hoechst 33342 (DNA) (PDGFR␤-pY1021 indicates PDGFR␤ autophosphorylated on Tyr1021). B, Protein fluorescence intensity was quantitated as described in Methods, and normalized within each staining group to WT samples to obtain fold greater than control. The meansϮSE of Ն4 specimens in each genotype are plotted. Scale barsϭ50 m. Compared with control: *PϽ0.01. C, Sections from carotid grafts harvested 6 weeks postoperatively were stained with a modified connective tissue stain. Scale barsϭ100 m. D, Neointimal, medial, and cross sectional area are plotted as meansϮSE from Ն6 specimens of each genotype. Compared with WT grafts: *PϽ0.03.
GRK5 Regulates SMC PDGFR␤s by Enhancing Ubiquitination
Our carotid graft and carotid endothelial denudation studies implicated GRK5 in reducing atherogenic SMC activation.
To determine more directly whether GRK5 activity reduces atherogenic SMC activation, 16 we assayed primary SMCs from WT and congenic Grk5 Ϫ/Ϫ mice for migration and proliferation (Ն3 lines from each genotype). Proliferation in response to PDGF was 80Ϯ30% greater in Grk5 Ϫ/Ϫ than in WT SMCs ( Figure 4A ). Furthermore, migration in Grk5 Ϫ/Ϫ SMCs was 1.7-to 3-fold greater than that in WT SMCs, in response to platelet-derived growth factor, serum, or the multiple cytokines present in conditioned medium from activated Ms 20 ( Figure 4B ). Thus, SMC GRK5 reduces SMC migration and proliferation evoked by atherogenic stimuli, both in vitro ( Figure 4 ) and in vivo (Supplemental Figure IV ). Despite this apparent antiproliferative role for GRK5 in SMCs, the proliferation of Grk5 Ϫ/Ϫ and WT ECs was indistinguishable (data not shown).
To discern mechanisms for long-term GRK5-mediated PDGFR␤ desensitization pertinent to SMC proliferation and migration, we tested whether GRK5 could augment PDGFR␤ ubiquitination, a process that triggers PDGFR␤ degradation in the lysosome. 25 As Figure 4C demonstrates, WT and Grk5 Ϫ/Ϫ SMCs had indistinguishable levels of ubiquitin and the PDGFR␤ ubiquitin E3 ligase Cbl. Nonetheless, ubiquitination of the PDGFR␤ was 2.6Ϯ0.6-fold greater in WT than in Grk5 Ϫ/Ϫ SMCs (PϽ0.02), even though ubiquitination of the epidermal growth factor receptor was equivalent in the 2 SMC types. Concordantly with these ubiquitination results, degradation of the PDGFR␤ occurred more rapidly in WT than in Grk5 Ϫ/Ϫ SMCs ( Figure 4C ). Thus, in a receptorspecific manner, GRK5 appears to enhance PDGFR␤ ubiquitination and degradation in SMCs.
Regulation of Monocyte Migration by GRK5
Because monocyte migration is integral to atherogenesis 16 and because GRK5 does not desensitize CXCR4-dependent lymphocyte migration, 2 we tested whether GRK5 affects monocyte migration. Monocytes isolated from the bone marrow of Grk5 Ϫ/Ϫ and WT mice (Ն5 each) showed equivalent expression levels of important monocyte chemotactic receptors 6 : the colony-stimulating factor-1 receptor (CSF-1R), a receptor tyrosine kinase, and the CC chemokine receptor-2, the 7 transmembrane receptor for monocyte chemoattractant protein-1 ( Figure 5 ). In response to the protein kinase C activator phorbol ester, Grk5 Ϫ/Ϫ and WT monocytes demonstrated equivalent migration ( Figure 5C ). However, in response to CSF-1, monocyte chemoattractant protein-1, or the Ն28 cytokines present in conditioned medium from our activated Ms, 20 migration was 2.0Ϯ0.3-fold greater in Grk5 Ϫ/Ϫ than in WT monocytes ( Figure 5C ). Thus, GRK5 desensitizes the monocyte migratory response triggered by the CSF-1R and CCR2 in a receptor-specific fashion. Nevertheless, the prevalence of monocytes among peripheral blood leukocytes was equivalent in Grk5 Ϫ/Ϫ /Apoe Ϫ/Ϫ and Grk5 ϩ/ϩ /Apoe Ϫ/Ϫ mice consuming a Western diet for 4 weeks (14Ϯ4%, nϭ4/genotype). Aortic ECs from wild-type (WT) and Grk5 Ϫ/Ϫ mice were serum starved and then exposed to serum-free medium lacking (basal) or containing murine tumor necrosis factor (TNF) (5 ng/mL)Ϯlipopolysaccharide (10 ng/mL) for the indicated times (A) or for 24 hours (B) and then lysed in SDS sample buffer. Results are from single experiments, representative of 3 performed of each type. A, EC lysates were immunoblotted (IB) in parallel for IB␣ or phospho-Ser32/36-IB␣ and then reprobed for tubulin. The IB␣/tubulin and phospho-IB␣/ IB␣ band density ratios were used for data reported in Results. B, EC lysates were immunoblotted serially for intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, actin, and GRK5. The IgG (A16/17) for GRK5 immunoblotting recognizes GRK5 and GRK6, 17 which comigrates with GRK5 and can be seen in Grk5 Ϫ/Ϫ lanes. Isotype control IgG yielded no corresponding bands (not shown). C, ICAM-1 and VCAM-1 bands were normalized to cognate actin bands; these ratios are plotted as meansϮSE from 3 independent experiments with independently isolated Grk5 Ϫ/Ϫ and WT ECs. Compared with WT: *PϽ0.03. D, Lysates from unstimulated ECs were immunoblotted serially for the indicated proteins (p65 denotes NF-B subunit p65). Parallel experiments with smooth muscle cells (SMCs) yielded congruent results (not shown).
Pathway-Specific Regulation of M TLR4 and TNFR1 by GRK5
Thus far, we have seen pleiotropic antiatherogenic activities of GRK5 in SMCs, ECs, and monocytes. However, GRK5 has been reported to mediate potentially proatherogenic signaling in Ms by augmenting TLR4-or TNFR1-promoted NF-B activity. 13, 14 To assess this issue further, we compared NF-B activation between 2 types of WT and Grk5 Ϫ/Ϫ Ms: bone marrow-derived (5 lines/genotype) and thioglycollateelicited (from the peritoneum, 2 lines/genotype); both M types yielded equivalent results. GRK5 protein expression in WT Ms was equivalent to that in SMCs (Supplemental Figure VI) . Following stimulation of TLR4 or TNFR1, Figure VII) , IL-1␣, 27 IL-6, 28 IL-12, 29 and TNF 30 (ELISA data not shown). Importantly, there were equivalent levels of TLR4, TNFR1, IB kinase-␤, and IB␣ in Grk5 Ϫ/Ϫ and WT Ms (Supplemental Figures VII and VIII) . Thus, in Ms, GRK5 neither increased nor decreased NF-B activity, even though GRK5 decreased NF-B activity in SMCs and ECs (Figures 2 and 3) .
Although NF-B signaling was equivalent in WT and Grk5 Ϫ/Ϫ Ms, extracellular signal-regulated kinase (ERK) signaling was not. M ERK1/2 signaling elicited via TLR4 or TNFR1 was Ϸ50% greater in Grk5 Ϫ/Ϫ than in WT Ms (PϽ0.05), even though M ERK1/2 signaling elicited by phorbol ester was equivalent in Grk5 Ϫ/Ϫ and WT Ms (Supplemental Figures VII and VIII) . Thus, M GRK5 reduced TLR4-and TNFR1-induced ERK1/2 signaling in a receptor-specific manner.
GRK5 Reduces M CSF-1R Activation
Because M proliferation is augmented in Grk5 Ϫ/Ϫ atheromata ( Figure 1 ) and because signaling through the CSF-1R is Figure 4 . G protein-coupled receptor kinase-5 (GRK5) reduces platelet-derived growth factor (PDGF)-evoked smooth muscle cell (SMC) proliferation and migration and augments platelet-derived growth factor receptor-␤ (PDGFR␤) ubiquitination/degradation. A, Quiescent SMCs were exposed to 2.5% fetal bovine serum (FBS) without (basal) or with 2 nmol/L PDGF-BB; at each time point, SMC number was normalized to wild-type (WT) SMC number quantitated after 8 days' proliferation to obtain percentage of control. Shown are meansϮSE from independent experiments with 5 independent Grk5 Ϫ/Ϫ and WT SMC lines. Compared with the WT growth curve: *PϽ0.05. B, Quiescent SMCs were placed on membranes of modified Boyden chambers containing serum-free medium without (basal) or with 2 nmol/L PDGF-BB, 10% FBS, or a confluent layer of activated macrophages (Ms). (Results were equivalent when either Grk5 Ϫ/Ϫ or WT Ms were used [data not shown].) Migrated SMCs are plotted as meansϮSE from 3 experiments with independently isolated WT and Grk5 Ϫ/Ϫ SMCs. Compared with WT SMCs: *PϽ0.05. C, Quiescent SMCs were exposed to serum-free medium lacking or containing either PDGF-BB (2 nmol/L) or epidermal growth factor (EGF) (1.2 nmol/L) for 10 minutes (37°C). SMC lysates were divided and subjected to (1) immunoprecipitation (IP) for PDGFR␤ or EGF receptor (EGFR), followed by SDS-PAGE and sequential immunoblotting (IB) for ubiquitin (Ubiq) and PDGFR␤ or EGFR (top), or (2) IB for the indicated SMC proteins (bottom). Results from a single experiment represent 4 performed. D, SMCs were exposed to mediumϮ2 nmol/L PDGF-BB for the indicated times and then lysed. Lysates were subjected to serial IB for PDGFR␤ and tubulin; immunoblots from 2 time points of a single experiment are shown (top). PDGFR␤ band densities were normalized to cognate tubulin band densities; these ratios were normalized to those obtained for unstimulated WT SMCs to obtain percentage of control, plotted as meansϮSE from 3 independent experiments performed with independently isolated pairs of WT and Grk5 Ϫ/Ϫ SMC lines (bottom panel). Compared with the WT PDGFR␤ degradation curve: *PϽ0.05.
critical for M proliferation, 31 we tested whether GRK5 affected CSF-1R activation. Although CSF-1R density was equivalent in WT and Grk5 Ϫ/Ϫ Ms, agonist-induced autophosphorylation of the CSF-1R was 50Ϯ20% greater in Grk5 Ϫ/Ϫ than in WT Ms (PϽ0.05, Figure 6 and data not shown). Congruently, CSF-1R-triggered Akt activation was 50Ϯ20% greater (nϭ5, PϽ0.03) and ERK activation was 34Ϯ7% greater (nϭ4, PϽ0.05) in Grk5 Ϫ/Ϫ than in WT Ms, even though ERK activation evoked by phorbol ester was equivalent among WT and Grk5 Ϫ/Ϫ Ms ( Figure 6C and Supplemental Figure VIIIC) . Concordant data among 5 pairs of independently isolated WT and Grk5 Ϫ/Ϫ M lines strongly supported the inference that changes in CSF-1R activity were GRK5-dependent.
GRK5 activity reduces receptor tyrosine kinase autophosphorylation of both the CSF-1R ( Figure 6 ) and the PDGFR␤. 17 However, GRK5 appeared to achieve different effects on agonist-induced ubiquitination of these 2 receptors, even though the ubiquitin E3 ligase Cbl plays a major role in ubiquitination of both receptors. 32, 33 Whereas GRK5 enhanced PDGFR␤ ubiquitination in SMCs ( Figure 4C ), it did not affect CSF-1R ubiquitination in Ms ( Figure 6A ). Despite failing to augment CSF-1R ubiquitination, GRK5 appeared to mediate long-term M CSF-1R desensitization: CSF-1-induced proliferation was 31Ϯ7% greater in Grk5 Ϫ/Ϫ than in WT Ms over 3 days (PϽ0.02, Figure 6D ), congruent with the 67% increased prevalence of S-phase Ms observed in Grk5 Ϫ/Ϫ /Apoe Ϫ/Ϫ atheromata (Figure 1) . Thus, GRK5 appears to use overlapping but distinct mechanisms of regulation for the related receptor tyrosine kinases PDGFR␤ and CSF-1R.
Discussion
Our data demonstrate the novel finding that GRK5 activity attenuates atherosclerosis, and that it does so through distinct antiatherogenic mechanisms in ECs, SMCs, monocytes, and Ms. These cell-specific mechanisms encompass diverse signaling systems, including the receptor tyrosine kinases CSF-1R and PDGFR␤, the 7-transmembrane receptor CCR2, the innate immunity receptors TLR4 and TNFR1, and the transcription factor NF-B. Thus, despite data from overexpression and model cell systems suggesting the possibility that GRK5 could mediate proatherogenic activities, 9, 11, 13, 14 net physiological GRK5 activity clearly appears to be antiatherogenic.
Because GRK5-mediated phosphorylation of 7-transmembrane receptors promotes receptor/␤-arrestin association, 1 it may seem paradoxical that whereas GRK5 activity is antiatherogenic, ␤-arrestin2 activity is proatherogenic. 19 However, at least 2 possibilities may help reconcile these findings. First, GRK5mediated receptor phosphorylation may promote the association of receptors with ␤-arrestin1 more so than with ␤-ar-restin2-and because ␤-arrestin1 can exert effects antagonistic to ␤-arrestin2 (particularly in SMCs), 19 the global effect of GRK5-mediated phosphorylation may result from a balance of ␤-arrestin isoform activity that favors ␤-arrestin1. Second, even if it does promote atherogenic ␤-arrestin2 activity, SMC GRK5 may still achieve overall antiatherogenic effects by diminishing atherogenic PDGFR␤ signaling, 17, 18 which is not affected by ␤-arrestin2 in SMCs 19 even though the PDGFR␤ is phosphorylated by GRK5 in SMCs. 17 Our study reveals a novel mechanism by which GRK5 alters PDGFR␤ signaling: enhancing PDGFR␤ ubiquitination, which enhances PDGFR␤ degradation. GRK5-mediated seryl phosphorylation of the PDGFR␤ may trigger ubiquitin E3 ligase activity in a manner analogous to the Ser/Thr kinase IB kinase-␤, with which GRK5 (under specific conditions) appears to share the substrate IB␣. 13 Our work is the first to demonstrate that GRK5 regulates the CSF-1R, a receptor tyrosine kinase belonging to the PDGFR␤ subfamily, 31 through mechanisms distinct, in part, from those that obtain with the PDGFR␤. Whereas GRK5 reduces Tyr autophosphorylation of both receptors and signaling downstream of both receptors, it enhances ubiquitination of only the PDGFR␤ (Figures 4 and 6 ). 17 This receptorspecific difference in agonist-promoted ubiquitination is particularly notable because Cbl is believed to be a major E3 ubiquitin ligase acting on both receptors. 32, 33 Whereas GRK5 reduces SMC and M proliferation promoted through the PDGFR␤ and CSF-1R, respectively, it reduces ERK signaling evoked only by the CSF-1R (Figures 4 and 6 ). 17 The CSF-1R is known to be phosphorylated on Ser residues, 31 but it remains to be established whether GRK5 mediates this phosphorylation.
Our carotid transplant data support the view that GRK5 activity in SMCs and ECs reduces atherogenesis. That SMC proteins can exert antiatherogenic activity has been demonstrated in only a limited number of instances. SMC-specific deletion of low-density lipoprotein receptor-related protein, perhaps by engendering upregulation of SMC PDGFR␤s, augments atherosclerosis in Ldlr Ϫ/Ϫ mice. 24 SMC-specific deletion of peroxisome proliferator-activated receptor-␥ also augments atherosclerosis in Ldlr Ϫ/Ϫ mice. 34 In a similar fashion, our surgically chimeric mouse carotid graft model shows that SMC GRK5 reduces not only PDGFR␤ activation but also NF-B activation (Figure 2 ). The mechanism of GRK5-mediated inhibition of NF-B activity may be the ability of GRK5 to bind to IB␣ and prevent its degradation, as demonstrated in overexpression systems. 15 Although we found that GRK5 reduces NF-B activity in ECs and SMCs, we found that GRK5 has no effect on NF-B activity in Ms. Our M findings contrast with those obtained by others, 14 who found that GRK5 increased M NF-B activity-but in Ms from Grk5 Ϫ/Ϫ and WT mice that were backcrossed only 5 generations to C57BL/6 and used as nonlittermates 14 (instead of our C57BL/6-congenic mice). Thus, interstrain differences in loci other than Grk5 could well have confounded these previous studies. In purified protein preparations, GRK5 can phosphorylate IB␣ on the Ser32/Ser36 residues targeted by IB kinase-␤ 13 ; however, phospholipids that normally enhance GRK5 activity 1 Figure 6 . G protein-coupled receptor kinase-5 (GRK5) activity in macrophages (Ms) reduces colony-stimulating factor-1 receptor (CSF-1R)-induced signaling and proliferation. A to C, Quiescent bone marrow-derived Ms were exposed to serum-free medium lacking (Ϫ) or containing (ϩ) 1.7 nmol/L CSF-1 for 10 minutes (37°C) and lysed. A, M lysates were subjected to immunoprecipitation (IP) with anti-CSF-1R or nonimmune (Ϫ) IgG; immunoprecipitates were subjected to parallel SDS-PAGE and serial immunoblotting (IB) for CSF-1R and then either phospho-Tyr (pY) or ubiquitin (Ubiq). B, Ubiquitin and pY band densities were normalized to cognate CSF-1R band densities; these ratios were normalized to CSF-1-stimuated wild-type (WT) Ms in each experiment, to obtain percentage of WT, plotted as meansϮSE of 4 experiments with independently isolated pairs of WT and Grk5 Ϫ/Ϫ M lines. Compared with WT: *PϽ0.05. C, M lysates (40 g protein/lane) were immunoblotted for the indicated proteins. Bands for pAkt and pERK1/2 were normalized to the GRK2 loading control within each experiment; ratios were normalized to CSF-1-stimulated WT Ms for quantitation. Results from a single experiment represent 3 performed with independently isolated pairs of WT and Grk5 Ϫ/Ϫ M lines. Blots probed with isotype control primary IgG yielded no corresponding bands (not shown). D, Bone marrow-derived Ms from WT and Grk5 Ϫ/Ϫ mice were cultured in the presence of CSF-1, and the number of Ms per well were determined at the indicated times. Shown are the meansϮSE of 4 experiments performed with 4 independently isolated pairs of WT and Grk5 Ϫ/Ϫ M lines. Compared with WT growth curve: *PϽ0.02. ERK indicates extracellular signal-regulated kinase.
actually inhibit GRK5-mediated phosphorylation of IB␣. 13 Therefore, it seems likely that GRK5-mediated IB␣ phosphorylation would be relatively inhibited in intact cells. Although it is conceivable that under particular circumstances GRK5 may contribute to NF-B activation, 14 it does not appear to do so in the context of atherogenesis.
Although little is known about factors that upregulate GRK5 in a manner that could mitigate atherosclerosis, we have found that endogenous GRK5 upregulates in SMCs and ECs during atherogenesis (Supplemental Figure III) . Could increased GRK5 activity reduce atherosclerosis in humans? Such a possibility is suggested by studies of the human GRK5 Gln41Leu polymorphism (rs17098707). GRK5-Leu41 effects greater desensitization of the 7-transmembrane ␤ 1 -adrenergic receptor than GRK5-Gln41 35 ; the GRK5-Leu41 variant has been associated with reduced mortality in humans with chronic heart failure 35 and with reduced adverse cardiovascular events in a case-control study of hypertensive humans with coronary artery disease. 36 Whether these associations reflect a causal inverse relationship between GRK5 activity and mortality remains uncertain. However, if a causal relationship does exist, the most plausible mechanism would involve GRK5-mediated desensitization of the ␤ 1 -adrenergic receptor, hyperstimulation of which can engender sudden cardiac death in subjects who experience chronic heart failure or acute myocardial infarction. 35, 37, 38 It remains to be determined whether enhancing GRK5 expression or activity to mitigate atherosclerosis will prove practicable.
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